David C Wraith

List of Publications by Year
in descending order

138	12,763	36303	24258
papers	citations	51 h-index	110 g-index

147	147	147	11091
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell, 1986, 44, 959-968.	28.9	1,746
2	Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. Cell, 1988, 54, 263-273.	28.9	996
3	IL-10-Secreting Regulatory T Cells Do Not Express Foxp3 but Have Comparable Regulatory Function to Naturally Occurring CD4+CD25+ Regulatory T Cells. Journal of Immunology, 2004, 172, 5986-5993.	0.8	583
4	Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. Cell, 1989, 59, 247-255.	28.9	399
5	Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity, 1995, 3, 407-415.	14.3	396
6	Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature, 1996, 379, 343-346.	27.8	382
7	Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice.. Journal of Experimental Medicine, 1993, 178, 1783-1788.	8.5	327
8	Vaccination and autoimmune disease: what is the evidence?. Lancet, The, 2003, 362, 1659-1666.	13.7	307
9	Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature Medicine, 2005, 11, S69-S76.	30.7	290
10	Cutting Edge: Th1 Cells Facilitate the Entry of Th17 Cells to the Central Nervous System during Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2008, 181, 3750-3754.	0.8	289
11	Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. International Immunology, 1993, 5, 1159-1165.	4.0	281
12	Regulation of Adaptive Immunity; The Role of Interleukin-10. Frontiers in Immunology, 2013, 4, 129.	4.8	251
13	SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study. Thorax, 2020, 75, 1089-1094.	5.6	234
14	Role for IL-10 in Suppression Mediated by Peptide-Induced Regulatory T Cells In Vivo. Journal of Immunology, 2003, 170, 1240-1248.	0.8	233
15	T cell recognition as the target for immune intervention in autoimmune disease. Cell, 1989, 57, 709-715.	28.9	218
16	Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nature Immunology, 2002, 3, 169-174.	14.5	200
17	Domain interactions of Hâ€“2 class I antigens alter cytotoxic T-cell recognition sites. Nature, 1984, 309, 279-281.	27.8	186
18	TGF-Î²-dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. Journal of Hepatology, 2014, 61, 594-599.	3.7	185

#	Article	IF	Citations
19	Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. International Immunology, 1999, 11, 1625-1634.	4.0	183
20	Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Immunity, 2017, 47, 875-889.e10.	14.3	181
21	An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. International Immunology, 1993, 5, 1151-1158.	4.0	180
22	Negative Selection during the Peripheral Immune Response to Antigen. Journal of Experimental Medicine, 2001, 193, 1-12.	8.5	161
23	A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.. Proceedings of the National Academy of Sciences of the United States of America, 1991, 88, 9633-9637.	7.1	159
24	Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nature Communications, 2014, 5, 4741.	12.8	147
25	Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10â€“secreting Th1 cells. Journal of Experimental Medicine, 2009, 206, 1755-1767.	8.5	145
26	Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. Journal of Hepatology, 2015, 62, 1349-1356.	3.7	145
27	Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. Journal of Clinical Investigation, 2008, 118, 3403-10.	8.2	142
28	Selection and fine-tuning of the autoimmune T-cell repertoire. Nature Reviews Immunology, 2002, 2, 487-498.	22.7	138
29	Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage. Gene, 1993, 128, 79-83.	2.2	130
30	Antigen-specific immunotherapy of autoimmune and allergic diseases. Current Opinion in Immunology, 2010, 22, 609-615.	5.5	118
31	Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neuroscience Letters, 2008, 448, 71-73.	2.1	116
32	Regulatory CD4+ T cells and the control of autoimmune disease. Current Opinion in Immunology, 2004, 16, 695-701.	5.5	107
33	Early growth response gene 2 (Egr-2) controls the self-tolerance of T cells and prevents the development of lupuslike autoimmune disease. Journal of Experimental Medicine, 2008, 205, 2295-2307.	8.5	105
34	Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nature Immunology, 2002, 3, 175-181.	14.5	97
35	Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. European Journal of Immunology, 1998, 28, 1251-1261.	2.9	93
36	Human Mesenchymal Stem Cells Infiltrate the Spinal Cord, Reduce Demyelination, and Localize to White Matter Lesions in Experimental Autoimmune Encephalomyelitis. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1087-1095.	1.7	85

#	Article	IF	Citations
37	IL-4 enhances IL-10 production in Th1 cells: implications for Th1 and Th2 regulation. Scientific Reports, 2017, 7, 11315.	3.3	82
38	Comment on â€œExpression of Helios, an Ikaros Transcription Factor Family Member, Differentiates Thymic-Derived from Peripherally Induced Foxp3+ T Regulatory Cellsâ€• Journal of Immunology, 2010, 185, 7129-7129.	0.8	79
39	The adaptive immune system in diseases of the central nervous system. Journal of Clinical Investigation, 2012, 122, 1172-1179.	8.2	79
40	The Future of Immunotherapy: A 20-Year Perspective. Frontiers in Immunology, 2017, 8, 1668.	4.8	76
41	Affinity for class II MHC determines the extent to which soluble peptides tolerize autoreactive T cells in naive and primed adult miceâ€”implications for autoimmunity. International Immunology, 1995, 7, 1255-1263.	4.0	73
42	Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study. Thyroid, 2019, 29, 1003-1011.	4.5	72
43	IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. Journal of Neuroimmunology, 2006, 178, 1-8.	2.3	70
44	Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e93.	6.0	70
45	Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis. Neurology, 2018, 90, e955-e962.	1.1	66
46	Lowering the tone: mechanisms of immunodominance among epitopes with low affinity for MHC. Trends in Immunology, 1996, 17, 80-85.	7.5	65
47	CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood, 2012, 119, 4073-4082.	1.4	62
48	Persistent antigenic stimulation alters the transcription program in Tâ€„cells, resulting in antigen-specific tolerance. European Journal of Immunology, 2006, 36, 1374-1385.	2.9	61
49	Mechanisms of central and peripehral T-cell tolerance: lessons from experimental models of multiple sclerosis. Immunological Reviews, 1999, 169, 123-137.	6.0	59
50	Tr1-Like T Cells â€“ An Enigmatic Regulatory T Cell Lineage. Frontiers in Immunology, 2016, 7, 355.	4.8	59
51	Antigenic strength controls the generation of antigenâ€specific ILâ€10â€secreting T regulatory cells. European Journal of Immunology, 2010, 40, 1386-1395.	2.9	54
52	Mucosal Tolerance in a Murine Model of Experimental Autoimmune Encephalomyelitisa. Annals of the New York Academy of Sciences, 1996, 778, 228-242.	3.8	52
53	Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection. Clinical and Experimental Immunology, 2021, 205, 99-105.	2.6	52
54	Epigenetic modification of the PD-1 (Pdcd1) promoter in effector CD4+ T cells tolerized by peptide immunotherapy. ELife, 2014, 3, .	6.0	52

#	Article	IF	Citations
55	Detection of autoreactive T cells in H-2u mice using peptideâ€“MHC multimers. International Immunology, 2000, 12, 1553-1560.	4.0	50
56	Nr4a1 and Nr4a3 Reporter Mice Are Differentially Sensitive to T Cell Receptor Signal Strength and Duration. Cell Reports, 2020, 33, 108328.	6.4	50
57	Enhanced selection of FoxP3 ⁺ T-regulatory cells protects CTLA-4-deficient mice from CNS autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3306-3311.	7.1	48
58	Phenotypic analysis of CTLA-4 and CD28 expression during transient peptide-induced T cell activation in vivo. International Immunology, 1999, 11, 667-675.	4.0	47
59	A role for galanin in human and experimental inflammatory demyelination. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 15466-15471.	7.1	44
60	Glycogen synthase kinaseâ€3 controls ILâ€10 expression in CD4⁺ effector Tâ€cell subsets through epigenetic modification of the ILâ€10 promoter. European Journal of Immunology, 2015, 45, 1103-1115.	2.9	44
61	CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E221-30.	7.1	43
62	Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. Blood, 2003, 102, 3800-3806.	1.4	42
63	Therapeutic peptide vaccines for treatment of autoimmune diseases. Immunology Letters, 2009, 122, 134-136.	2.5	42
64	Combinations of CD45 Isoforms Are Crucial for Immune Function and Disease. Journal of Immunology, 2006, 176, 3417-3425.	0.8	41
65	The role of cytokines in immunological tolerance: potential for therapy. Expert Reviews in Molecular Medicine, 2000, 2, 1-20.	3.9	40
66	The recognition of influenza A virus- infected cells by cytotoxic T lymphocytes. Trends in Immunology, 1987, 8, 239-246.	7.5	35
67	Antigen-specific immunotherapy. Nature, 2016, 530, 422-423.	27.8	35
68	Immunotherapy With Apitopes Blocks the Immune Response to TSH Receptor in HLA-DR Transgenic Mice. Endocrinology, 2018, 159, 3446-3457.	2.8	35
69	Development of a highâ€sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARSâ€CoVâ€2 spike glycoprotein in serum and saliva. Immunology, 2021, 164, 135-147.	4.4	35
70	Intranasal peptide-induced peripheral tolerance: the role of IL-10 in regulatory T cell function within the context of experimental autoimmune encephalomyelitis. Veterinary Immunology and Immunopathology, 2002, 87, 357-372.	1.2	33
71	Antigen and checkpoint receptor engagement recalibrates TÂcell receptor signal strength. Immunity, 2021, 54, 2481-2496.e6.	14.3	33
72	Myeloidâ€derived suppressor cells mediate tolerance induction in autoimmune disease. Immunology, 2017, 151, 26-42.	4.4	32

#	Article	IF	Citations
73	Therapeutic potential of TCR antagonists is determined by their ability to modulate a diverse repertoire of autoreactive T cells. European Journal of Immunology, 1999, 29, 1850-1857.	2.9	30
74	The nature of cryptic epitopes within the self-antigen myelin basic protein. International Immunology, 1996, 8, 1035-1043.	4.0	29
75	Antigen-Induced IL-10+ Regulatory T Cells Are Independent of CD25+ Regulatory Cells for Their Growth, Differentiation, and Function. Journal of Immunology, 2006, 176, 5329-5337.	0.8	29
76	IL-2 Overcomes the Unresponsiveness but Fails to Reverse the Regulatory Function of Antigen-Induced T Regulatory Cells. Journal of Immunology, 2005, 174, 310-319.	0.8	28
77	Antigen-presenting Cell Activation: a Link Between Infection and Autoimmunity?. Journal of Autoimmunity, 2001, 16, 303-308.	6.5	26
78	Natural and Induced Regulatory T Cells. Annals of the New York Academy of Sciences, 2004, 1029, 180-192.	3.8	26
79	Extraâ€thymically induced <scp>T</scp> regulatory cell subsets: the optimal target for antigenâ€specific immunotherapy. Immunology, 2015, 145, 171-181.	4.4	25
80	Serological responses to SARS-CoV-2 following non-hospitalised infection: clinical and ethnodemographic features associated with the magnitude of the antibody response. BMJ Open Respiratory Research, 2021, 8, e000872.	3.0	25
81	Role of interleukin-10 in the induction and function of natural and antigen-induced regulatory T cells. Journal of Autoimmunity, 2003, 20, 273-275.	6.5	24
82	Searching for MHC-restricted anti-viral antibodies: antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of C57BL/6 mice to syngeneic influenza-infected cells. European Journal of Immunology, 1987, 17, 999-1006.	2.9	23
83	MHC-binding peptides for immunotherapy ofexperimental autoimmune disease. Journal of Autoimmunity, 1992, 5, 103-113.	6.5	23
84	Differential activation of signal transducer and activator of transcription (STAT)3 and STAT5 and induction of suppressors of cytokine signalling in Th1 and Th2 cells. International Immunology, 2003, 15, 1309-1317.	4.0	23
85	Kinetics of Peptide Uptake and Tissue Distribution Following a Single Intranasal Dose of Peptide. Immunological Investigations, 2000, 29, 61-70.	2.0	22
86	Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases. Frontiers in Immunology, 2020, 11, 1586.	4.8	21
87	Chromatin Priming Renders T Cell Tolerance-Associated Genes Sensitive to Activation below theÂSignaling Threshold for Immune Response Genes. Cell Reports, 2020, 31, 107748.	6.4	21
88	Therapies for Long COVID in non-hospitalised individuals: from symptoms, patient-reported outcomes and immunology to targeted therapies (The TLC Study). BMJ Open, 2022, 12, e060413.	1.9	21
89	New inhibitory signaling by CTLA-4. Nature Immunology, 2014, 15, 408-409.	14.5	20
90	Preclinical models of arthritis for studying immunotherapy and immune tolerance. Annals of the Rheumatic Diseases, 2021, 80, 1268-1277.	0.9	20

#	Article	IF	Citations
91	Anti-cytokine vaccines and the immunotherapy of autoimmune diseases. European Journal of Immunology, 2006, 36, 2844-2848.	2.9	19
92	CD86 Has Sustained Costimulatory Effects on CD8 T Cells. Journal of Immunology, 2007, 179, 5936-5946.	0.8	18
93	CTLA-4 Modulates the Differentiation of Inducible Foxp3+ Treg Cells but IL-10 Mediates Their Function in Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2014, 9, e108023.	2.5	18
94	PKCÎ¸ links proximal T cell and Notch signaling through localized regulation of the actin cytoskeleton. ELife, 2017, 6, .	6.0	18
95	The role of CTLA-4 in immune regulation. Immunology Letters, 2008, 115, 73-74.	2.5	17
96	Activation thresholds determine susceptibility to peptide-induced tolerance in a heterogeneous myelin-reactive T cell repertoire. Journal of Neuroimmunology, 2004, 156, 96-106.	2.3	16
97	Variant proteins stimulate more IgM+ GC B-cells revealing a mechanism of cross-reactive recognition by antibody memory. ELife, 2018, 7, .	6.0	16
98	Blockade of LFA-1 augments in vitro differentiation of antigen-induced Foxp3+ Treg cells. Journal of Immunological Methods, 2014, 414, 58-64.	1.4	15
99	Designing antigens for the prevention and treatment of autoimmune diseases. Current Opinion in Chemical Engineering, 2018, 19, 35-42.	7.8	15
100	Peptide allergenâ€specific immunotherapy for allergic airway diseasesâ€" State of the art. Clinical and Experimental Allergy, 2021, 51, 751-769.	2.9	15
101	Manipulating antigen presentation for antigen-specific immunotherapy of autoimmune diseases. Current Opinion in Immunology, 2021, 70, 75-81.	5.5	14
102	Peptide-MHC interaction in autoimmunity. Current Opinion in Immunology, 1992, 4, 748-753.	5.5	13
103	SARSâ€CoVâ€2â€specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multiâ€System Syndrome. Pediatric Allergy and Immunology, 2021, 32, 1125-1129.	2.6	13
104	Loss of serological determinants does not affect recognition of H-2Kk target cells by an influenza-specific cytotoxic T cell clone. European Journal of Immunology, 1983, 13, 762-766.	2.9	12
105	Immunotherapy of autoimmune disease. Current Opinion in Immunology, 1993, 5, 925-933.	5.5	12
106	SARS-CoV-2 Spike- and Nucleoprotein-Specific Antibodies Induced After Vaccination or Infection Promote Classical Complement Activation. Frontiers in Immunology, 0, 13, .	4.8	12
107	Isolation and characterization of human interleukin-10â€"secreting T cells from peripheral blood. Human Immunology, 2010, 71, 225-234.	2.4	11
108	Cytotoxic T-cell recognition of influenza-infected target cells varies in different H-2 k mouse strains. Immunogenetics, 1983, 18, 177-181.	2.4	10

#	Article	IF	Citations
109	Cross-reactivity and T-cell Receptor Antagonism of Myelin Basic Protein-reactive T cells is Modulated by the Activation State of the Antigen Presenting Cell. Journal of Autoimmunity, 2002, 19, 183-193.	6.5	10
110	CNS infection safety signal of RTS,S/AS01 and possible association with rabies vaccine. Lancet, The, 2016, 387, 1376.	13.7	10
111	A humanized HLA-DR4 mouse model for autoimmune myocarditis. Journal of Molecular and Cellular Cardiology, 2017, 107, 22-26.	1.9	10
112	Modification of the FoxP3 Transcription Factor Principally Affects Inducible T Regulatory Cells in a Model of Experimental Autoimmune Encephalomyelitis. PLoS ONE, 2013, 8, e61334.	2.5	10
113	Induction of Antigen-Specific Unresponsiveness with Synthetic Peptides: Specific Immunotherapy for Treatment of Allergic and Autoimmune Conditions. International Archives of Allergy and Immunology, 1995, 108, 355-359.	2.1	9
114	Characterization of the Dominant Autoreactive T-cell Epitope in Spontaneous Autoimmune Haemolytic Anaemia of the NZB Mouse. Journal of Autoimmunity, 2002, 18, 149-157.	6.5	9
115	IDENTIFICATION OF AN INDIRECTLY PRESENTED EPITOPE IN A MOUSE MODEL OF SKIN ALLOGRAFT REJECTION1. Transplantation, 1998, 65, 1357-1364.	1.0	9
116	Dk-restricted antiinfluenza cytotoxic t-cell clone loses one of its two alloreactivities. Immunogenetics, 1984, 20, 131-139.	2.4	8
117	T Cell Recognition in Experimental Autoimmune Encephalomyelitis: Prospects for Immune Intervention with Synthetic Peptides. International Reviews of Immunology, 1990, 6, 37-47.	3.3	8
118	Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy. Lancet Rheumatology, The, 2020, 2, e712-e723.	3.9	8
119	Protein kinase C theta is required for efficient induction of IL-10-secreting T cells. PLoS ONE, 2017, 12, e0171547.	2.5	8
120	PROLONGATION OF MURINE VASCULARIZED HEART ALLOGRAFT SURVIVAL BY RECIPIENT-SPECIFIC ANTI-MAJOR HISTOCOMPATIBILITY COMPLEX CLASS II ANTIBODY1. Transplantation, 1997, 64, 525-528.	1.0	7
121	The Mechanism of Action of Antigen Processing Independent T Cell Epitopes Designed for Immunotherapy of Autoimmune Diseases. Frontiers in Immunology, 2021, 12, 654201.	4.8	6
122	Induction of Tolerance to Therapeutic Proteins With Antigen-Processing Independent T Cell Epitopes: Controlling Immune Responses to Biologics. Frontiers in Immunology, 2021, 12, 742695.	4.8	6
123	Avidity and the Art of Self Non-Self Discrimination. Immunity, 2006, 25, 191-193.	14.3	5
124	Experimental autoimmune encephalomyelitis in mice expressing the autoantigen MBP1â€“10 covalently bound to the MHC class II molecule I-Au. International Immunology, 2006, 18, 151-162.	4.0	5
125	T-cell receptor degeneracy: the dog that did not barkAdaptation of the self-reactive T-cell response to limit autoimmune disease. Molecular Immunology, 2004, 40, 997-1002.	2.2	4
126	Antigen-specific immunotherapy with apitopes suppresses generation of FVIII inhibitor antibodies in HLA-transgenic mice. Blood Advances, 2021, , .	5.2	4

#	Article	IF	Citations
127	Immunotherapy of autoimmune disease with synthetic peptides. Trends in Immunology, 1994, 15, 91.	7.5	3
128	Natural and Induced Regulatory T Cells: Targets for Immunotherapy of Autoimmune Disease and Allergy. Inflammation and Allergy: Drug Targets, 2006, 5, 141-148.	1.8	3
129	Peptide-based therapy for autoimmune diseases. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 35-40.	0.5	2
130	Stem Cell Immunology. , 2008, , 199-213.		2
131	Adaptive T cell tuning in immune regulation and immunotherapy of autoimmune diseasesâœ°. Immunology Letters, 2022, 244, 12-18.	2.5	2
132	A role for major histocompatibility complex-binding peptides in the immunotherapy of autoimmune disease. Seminars in Immunopathology, 1992, 14, 95-101.	4.0	1
133	Therapeutic immunosuppression of T cells. Current Opinion in Biotechnology, 1992, 3, 668-674.	6.6	1
134	A hazardous vapour trail from abattoir to neuropathy clinic. Lancet Neurology, The, 2010, 9, 22-24.	10.2	0
135	A LAT-Based Signaling Complex in the Immunological Synapse as Determined with Live Cell Imaging Is Less Stable in T Cells with Regulatory Capability. Cells, 2021, 10, 418.	4.1	0
136	Human CD4+CD25+CD127â^' T Cells Show Potent Dose-Dependent Inhibition of Allogeneic DC-Driven MLRs.. Blood, 2006, 108, 5172-5172.	1.4	0
137	Human CD4+CD25+ regulatory T Cells Exhibit Dual Mechanisms of Action in Suppressing in Vitro Alloreactivity. Blood, 2008, 112, 2582-2582.	1.4	0
138	2 Are mesenchymal stem cells immune privileged?. , 2013, , 17-36.		0